← Back to Patent Explorer
US4512987A Expired / Lapsed US ⏱️ 0.0 years remaining

New pharmaceutical preparations

Assignee: Novartis Corp
•
Filing: 1982-10-13
•
Granted: 1985-04-23
•
Expires: 2002-10-13
📄 Original PDF 🌐 Google Patents 🔄 Sync Now

Abstract

Abstract The invention concerns new pharmaceutical preparations for topical administration, such as creams, ointments, foams, pastes or gels, which contain the anti-inflammatorily active glucocorticoid 2-chloro-6α,9α-difluoro-16α-methyl-11β,17α,21-trihydroxy-pregna-1,4-diene-3,20-dione (2-chloroflumethasone, halometasone) and the antimicrobial agent 2,4,4'-trichloro-2'-hydroxy-diphenyl ether (triclosan). The new dermatics may contain, besides these two components, pharmaceutical carriers as usually present in formulations for topical administration. The new dermatics are especially suitable for the treatment of inflected forms of acute eczematous dermatoses of different origin, for the initial treatment of strongly inflamed dermatomycoses or strongly inflamed forms of pyodermias.

Inventors

  • 👤 Ctibor Schindlery

Bibliographic Details

Application Number —
Jurisdiction US
Data Source google_patents
Last Synchronized 2026-10-28 01:58
CPC Classifications
A; A61; A61K; A61K31/00; A61K31/56; A61K31/57; A61P; A61P29/00; A61P31/00; A61P31/04

Claims Analysis

Total Claims: 11
Claim 1
Independent Claim 47 words
A pharmaceutical preparation for topical administration which contains the corticoid, 2-chloro-6α,9α-difluoro-16α-methyl 11β, 17α, 21-trihydroxy-pregna-1,4-diene-3,20-dione, and the antimicrobial agent, 2,4,4'-trichloro-2'-hydroxy-diphenyl ether, said preparation containing in the range of from about 0.01% to about 2.5% of said corticoid and from about 0.1% to about 5% of said antimicrobial agent.
Claim 2
Dependent Claim 47 words
A pharmaceutical preparation for topical administration which contains the corticoid, 2-chloro-6α,9α-difluoro-16α-methyl 11β, 17α, 21-trihydroxy-pregna-1,4-diene-3,20-dione, and the antimicrobial agent, 2,4,4'-trichloro-2'-hydroxy-diphenyl ether, said preparation containing in the range of from about 0.01% to about 2.5% of said corticoid and from about 0.1% to about 5% of said antimicrobial agent.
Claim 3
Dependent Claim 31 words
A pharmaceutical preparation according to claim 1, containing in the range of about 0.02% to about 0.8% of said corticoid and from about 0.5% to about 3% of said antimicrobial agent.
Claim 4
Dependent Claim 18 words
Pharmaceutical preparation as claimed in claim 1 in the form of a cream, ointment, paste, foam or gel.
Claim 5
Dependent Claim 13 words
A pharmaceutical preparation according to claim 1 in the form of a cream.
Claim 6
Dependent Claim 13 words
A pharmaceutical preparation according to claim 2 in the form of a cream.
Claim 7
Dependent Claim 31 words
A pharmaceutical preparation according to claim 1, containing in the range of about 0.03% to about 0.1% of said corticoid and from about 0.7% to about 2% of said antimicrobial agent.
Claim 8
Dependent Claim 23 words
A pharmaceutical preparation according to claim 5, having a content of about 0.05% of said corticoid and about 1% of said antimicrobial agent.
Claim 9
Dependent Claim 56 words
A method of treatment of infected or infection prone: acute contact dermatitus, acute endogenous eczema, acute nummular eczema, acute seborrhoeic eczema, impetigo contagiosa, ostiofolliculitis, inflamed folliculitis barbae, ecthyma, intertrigo, erythrasma or acute inflamed superficial dermatomycoses, comprising administering an effective amount of a pharmaceutical composition according to claim 1 to a patient in need of the same.
Claim 10
Dependent Claim 18 words
A method of treatment of infected dermatoses consisting in administering a pharmaceutical preparation as claimed in claim 1.
Claim 11
Dependent Claim 30 words
A method of treatment of infected acute eczematous dermatoses of different origin, for the initial treatment of strongly inflamed forms of pyodermia or strong inflamed dermatomycosis according to claim 9.

References Cited (Backward Citations)

GB1038185A Cited
US4076737A Cited
US4275061A Cited
US4298604A Cited
US4298604B1 Cited

USPTO Annuity & Maintenance Windows

Annuity Stage Window Opens Payment Deadline Surcharge Period Until Estimated Fee Status
3.5 Years (Year 4) 1988-04-22 1988-10-22 1989-04-23 $2000.00 Window Closed / Lapsed
7.5 Years (Year 8) 1992-04-22 1992-10-22 1993-04-23 $3760.00 Window Closed / Lapsed
11.5 Years (Year 12) 1996-04-22 1996-10-22 1997-04-23 $7700.00 Window Closed / Lapsed

Assigned Categories & Tags

No categories assigned to this patent yet.

Assign Category Tag